SpringWorks initiates Phase 1b trial of MEK inhibitor

SpringWorks Therapeutics reports that the first patient has been dosed in a Phase 1b study to evaluate the combination of SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, and BeiGene, Ltd.’s investigational RAF dimer inhibitor, lifirafenib (BGB-283), in patients with advanced or refractory solid tumors.

“Despite decades of research, no anti-RAS therapies have been approved to-date,” said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics. “This trial has the potential to meet a critical need for patients and is an important evolution for SpringWorks as it provides the opportunity to study our MEK inhibitor in patients with more commonly occurring tumors.”  more